DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc today reported its second quarter and first half 2012 financial results. “Progress continued during the course of the second quarter,” said Mr. Kelly Martin, chief executive officer. “Underlying strength in the Tysabri business was driven by continued adoption of the assay on a global basis, which established the clinical framework to enable additional net new patients to be added to Tysabri.”
